Skip to main content
. 2020 Jun;9(3):575–586. doi: 10.21037/tlcr-19-318

Table 2. Predictors of OS obtained from stepwise multivariate Cox regression analysis of selected variables in the PLCO Trial.

Variables1 Category Frequency3 HR (95% CI) P
Age Continuous 1,162 1.03 (1.02–1.05) <0.001
Sex Male 688 1.00
Female 474 0.80 (0.69–0.93) 0.005
Smoking status Never 114 1.00
Former 638 1.64 (1.25–2.16) <0.001
Current 410 1.65 (1.23–2.20) 0.001
Histology AD 570 1.00
SC 279 1.14 (0.94–1.37) 0.185
others 313 1.32 (1.11–1.57) 0.001
Stage I–IIIA 646 1.00
IIIB–IV 516 2.80 (2.31–3.40) <0.001
Chemotherapy No 630 1.00
Yes 532 0.58 (0.49–0.69) <0.001
Radiotherapy No 752 1.00
Yes 410 0.95 (0.81–1.12) 0.553
Surgery No 628 1.00
Yes 534 0.21 (0.16–0.27) <0.001
PLCG2 rs96736822 TT/TG/GG 513/518/131 0.85 (0.77–0.95) 0.003
PLPP1 rs1156139852 TT/TA/AA 451/545/166 1.17 (1.06–1.30) 0.003

1, stepwise analysis in the final model including age, sex, smoking status, tumor stage, histology, chemotherapy, radiotherapy, surgery, PC1, PC2, PC3, PC4 and two SNPs; 2, rs9673682 and rs115613985 in an additive genetic model. The leftmost genotype was used as the reference; 3, there were 23 samples with missing date and thus were excluded. OS, overall survival; PLCO, Prostate, Lung, Colorectal and Ovarian cancer screening trial; HR, hazards ratio; CI, confidence interval; AD, adenocarcinoma; SC, squamous cell carcinoma.